Experimental Hematology
Volume 37, Issue 8 , Pages 969-978 , August 2009

Secretory lysosome targeting and induced secretion of human soluble TNF-α receptor in murine hematopoietic cells in vivo as a principle for immunoregulation in inflammation and malignancy

  • Åsa C.M. Johansson

      Affiliations

    • Department of Hematology, Lund University Hospital, Lund, Sweden
    • ,
  • Kutty S. Nandakumar

      Affiliations

    • Medical Inflammation Research, Karolinska Institute, Stockholm, Sweden
    • ,
  • Ann-Maj Persson

      Affiliations

    • Department of Hematology, Lund University Hospital, Lund, Sweden
    • ,
  • Inge Olsson

      Affiliations

    • Department of Hematology, Lund University Hospital, Lund, Sweden
    • ,
  • Markus Hansson

      Affiliations

    • Department of Hematology, Lund University Hospital, Lund, Sweden
    • Corresponding Author InformationOffprint requests to: Markus Hansson, M.D., Ph.D., Department of Hematology, Lund University Hospital, SE-221 85 Lund, Sweden

Received 22 February 2009 ,Revised 11 May 2009 ,Accepted 22 May 2009.

References 

  1. Boxer L, Dale DC. Neutropenia: causes and consequences. Semin Hematol. 2002;39:75–81
  2. Gordon S. Elie Metchnikoff: Father of natural immunity. Eur J Immunol. 2008;38:3257–3264
  3. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819–826
  4. Dell'Angelica EC, Mullins C, Caplan S, Bonifacino JS. Lysosome-related organelles. FASEB J. 2000;14:1265–1278
  5. Gao Y, Tapper H, Calafat J, Olsson I, Hansson M. Granule targeting of soluble tumor necrosis factor (TNF) receptor expressed during granulopoietic maturation in murine bone marrow cells. Eur Cytokine Netw. 2006;17:98–108
  6. Gao Y, Rosen H, Johnsson E, Calafat J, Tapper H, Olsson I. Sorting of soluble TNF-receptor for granule storage in hematopoietic cells as a principle for targeting of selected proteins to inflamed sites. Blood. 2003;102:682–688
  7. Gao Y, Hansson M, Calafat J, Tapper H, Olsson I. Sorting soluble tumor necrosis factor (TNF) receptor for storage and regulated secretion in hematopoietic cells. J Leukoc Biol. 2004;76:876–885
  8. Hansson M, Jonsson S, Persson AM, Calafat J, Tapper H, Olsson I. Targeting proteins to secretory lysosomes of natural killer cells as a principle for immunoregulation. Mol Immunol. 2003;40:363–372
  9. Rous BA, Reaves BJ, Ihrke G, et al. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes. Mol Biol Cell. 2002;13:1071–1082
  10. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem. 2003;72:395–447
  11. Peden AA, Oorschot V, Hesser BA, Austin CD, Scheller RH, Klumperman J. Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal membrane proteins. J Cell Biol. 2004;164:1065–1076
  12. Harter C, Mellman I. Transport of the lysosomal membrane glycoprotein lgp120 (lgp-A) to lysosomes does not require appearance on the plasma membrane. J Cell Biol. 1992;117:311–325
  13. Janvier K, Bonifacino JS. Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins. Mol Biol Cell. 2005;16:4231–4242
  14. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis. 1999;58(Suppl 1):I32–I39
  15. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264:11974–11980
  16. Peetre C, Thysell H, Grubb A, Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol. 1988;41:414–419
  17. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med. 1988;167:1511–1516
  18. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15–25
  19. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol. 2001;19:163–196
  20. Ferrara JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol. 2008;21:677–682
  21. Bemelmans MH, Gouma DJ, Buurman WA. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J Immunol. 1993;151:5554–5562
  22. Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006;20:1181–1195
  23. Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf. 2008;7:617–632
  24. Lantz M, Gullberg U, Nilsson E, Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest. 1990;86:1396–1342
  25. Hawley RG. High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann N Y Acad Sci. 1994;716:327–330
  26. Kallquist L, Hansson M, Persson AM, et al. The tetraspanin CD63 is involved in granule targeting of neutrophil elastase. Blood. 2008;112:3444–3454
  27. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274:10689–10692
  28. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002;13:135–141
  29. Yokoo T, Utsunomiya Y, Ohashi T, et al. Inflamed site-specific gene delivery using bone marrow-derived CD11b + CD18+ vehicle cells in mice. Hum Gene Ther. 1998;9:1731–1738
  30. Yamagishi H, Yokoo T, Imasawa T, Mitarai T, Kawamura T, Utsunomiya Y. Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy. J Immunol. 2001;166:609–616
  31. Yokoo T, Ohashi T, Utsunomiya Y, et al. Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. Blood. 2001;98:57–64
  32. Boggs SS, Patrene KD, Mueller GM, Evans CH, Doughty LA, Robbins PD. Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Ther. 1995;2:632–638
  33. Doughty LA, Patrene KD, Evans CH, Boggs SS, Robbins PD. Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10. Gene Ther. 1997;4:252–257
  34. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther. 2003;10:902–911

PII: S0301-472X(09)00179-9

doi: 10.1016/j.exphem.2009.05.009

Experimental Hematology
Volume 37, Issue 8 , Pages 969-978 , August 2009

Article Tools

* Image Usage & Resolution